Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.

David Andrew  Sallman

Consulting or Advisory Role - Abbvie; Bluebird Bio; Bristol-Myers Squibb; Gilead Sciences; Intellia Therapeutics; Janssen; Kite, a Gilead company; Magenta Therapeutics; Molecular Partners; Novartis; Servier; Shattuck Labs; Syndax; Syros Pharmaceuticals; Takeda

Speakers' Bureau - Bristol-Myers Squibb; Incyte; SERVIER

Research Funding - Aprea Therapeutics (Inst); Jazz Pharmaceuticals

Monzr M.  Al Malki

Consulting or Advisory Role - CareDX; Gilead Sciences; Hansa Biopharma; Medexus Pharmaceuticals; NexImmune; Stemline Therapeutics

Research Funding - CareDX; Gilead Sciences; Incyte; NexImmune; Orca Bio

Adam Steven  Asch

Research Funding - Astellas Pharma (Inst); Cartesian Therapeutics (Inst); Forty Seven (Inst); Gilead Sciences (Inst); Juno Therapeutics (Inst); Macrogenics (Inst); MEI Pharma (Inst)

Patents, Royalties, Other Intellectual Property - Provisional patent submitted (I)

Eunice S.  Wang

Consulting or Advisory Role - Abbvie; Astellas Pharma; Celgene/Bristol-Myers Squibb; Genentech; Gilead Sciences; GlaxoSmithKline; Jazz Pharmaceuticals; Kite/Gilead; Novartis; Pfizer; Pharmaessentia; PTC Therapeutics; Stemline Therapeutics; Takeda

Speakers' Bureau - Astellas Pharma; dava oncology; Kite, a Gilead company; Pfizer; Stemline Therapeutics

Joseph G.  Jurcic

Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Jazz Pharmaceuticals; Novartis; Syros Pharmaceuticals

Research Funding - Abbvie (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb/Celgene (Inst); Celularity (Inst); FORMA Therapeutics (Inst); Gilead/Forty Seven (Inst); GlycoMimetics (Inst); PTC Therapeutics (Inst); Syros Pharmaceuticals (Inst)

(OPTIONAL) Uncompensated Relationships - Actinium Pharmaceuticals

Terrence J.  Bradley

Consulting or Advisory Role - Abbvie; Novartis

Ian W.  Flinn

Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Century Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); Great Point Partners (Inst); Hutchison MediPharma (Inst); Iksuda Therapeutics (Inst); Innocare (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Novartis (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst)

Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Path Holdings, Inc (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CALIBR (Inst); Celgene (Inst); City of Hope (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Curis (Inst); Fate Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Loxo (Inst); Merck (Inst); Millennium (Inst); MorphoSys (Inst); Myeloid Therapeutics (Inst); Novartis (Inst); Nurix (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Rhizen Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TCR2 Therapeutics (Inst); Tessa Therapeutics (Inst); TG Therapeutics (Inst); Triact Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)

Daniel Aaron  Pollyea

Consulting or Advisory Role - Abbvie; Agios; Amgen; Aprea Therapeutics; Astellas Pharma; Astellas Pharma; BeiGene; BerGenBio; Bristol-Myers Squibb; Celgene; Foghorn Therapeutics; Forty Seven; Genentech; Gilead Sciences; Glycomimetics; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Karyopharm Therapeutics; Kiadis Pharma; Novartis; Syndax; Syros Pharmaceuticals; Takeda

Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Celgene (Inst); Karyopharm Therapeutics (Inst); Teva (Inst)

Suman  Kambhampati

No Relationships to Disclose

Tiffany N.  Tanaka

Honoraria - OncLive

Consulting or Advisory Role - CTI BioPharma Corp

Joshua F.  Zeidner

Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Genentech; Gilead Sciences; SERVIER; Shattuck Labs; Takeda

Research Funding - Arog (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Gilead Sciences (Inst); Merck (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst)

Travel, Accommodations, Expenses - Agios; Celgene; Daiichi Sankyo; Dava Oncology; Forty Seven; Takeda; Tolero Pharmaceuticals

Guillermo  Garcia-Manero

Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis

Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb

Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis

Deepa  Jeyakumar

Research Funding - Jazz Pharmaceuticals; Pfizer

Lin  Gu

Employment - Gilead Sciences

Leadership - Gilead Sciences

Stock and Other Ownership Interests  - Gilead Sciences

Travel, Accommodations, Expenses - Gilead Sciences

Anderson  Tan

No Relationships to Disclose

Mark  Chao

Employment - Forty Seven; Gilead Sciences; TenSixteen Bio

Leadership - Forty Seven; TenSixteen Bio

Stock and Other Ownership Interests  - Chimera Bioengineering; Forty Seven; Gilead Sciences; Hepatx; TenSixteen Bio; TigaTx

Honoraria - D2G Oncology

Consulting or Advisory Role - Chimera Bioengineering

Patents, Royalties, Other Intellectual Property - I am an inventor on patents licensed to Hepatx Inc.; I am an inventor on several patents from Stanford University that have been licensed to Forty Seven, Inc. I am also an inventor on patents generated from Forty Seven, Inc.

Travel, Accommodations, Expenses - Forty Seven; Gilead Sciences; TenSixteen Bio

Carol Elaine  O'Hear

Employment - Genentech/Roche; Gilead Sciences

Stock and Other Ownership Interests  - Genentech/Roche

Patents, Royalties, Other Intellectual Property - Antibody buffering

Travel, Accommodations, Expenses - Genentech/Roche; Gilead Sciences

Indu  Lal

Employment - Abbvie/Pharmacyclics; Gilead Sciences; The Permanente Medical Group NorCal (I)

Stock and Other Ownership Interests  - Abbvie; Gilead Sciences; Reviva Pharmaceuticals (I)

Paresh  Vyas

Honoraria - Abbvie; Astellas Pharma; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; Pfizer

Research Funding - Celgene

Patents, Royalties, Other Intellectual Property - Patent for flow cytometric detection of leukaemic stem cells

Naval Guastad  Daver

Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Novartis; Pfizer; SERVIER; Shattuck Labs; Syndax; Trillium Therapeutics

Research Funding - Abbvie; Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; FATE Therapeutics; Genentech; Gilead Sciences; Glycomimetics; Hanmi; Immunogen; Novimmune; Pfizer; Servier; Trillium Therapeutics; Trovagene